Guided Therapeutics (GTHP) versus The Competition Head-To-Head Comparison

Guided Therapeutics (OTCMKTS:GTHP) is one of 78 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its competitors? We will compare Guided Therapeutics to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Guided Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	287	826	2137	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 2,855.87%. Given Guided Therapeutics’ competitors higher probable upside, analysts clearly believe Guided Therapeutics has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Guided Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-299.08%	-83.96%	-27.59%

Valuation and Earnings

This table compares Guided Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.33
Guided Therapeutics Competitors	$991.32 million	$83.13 million	9.81

Guided Therapeutics’ competitors have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Guided Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ competitors have a beta of 16.35, indicating that their average stock price is 1,535% more volatile than the S&P 500.

Summary

Guided Therapeutics competitors beat Guided Therapeutics on 7 of the 10 factors compared.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.